Loading…
Biotech selling Imcivree, a drug for rare genetic obesity disorders caused by defects in the MC4R pathway.
Biotech selling Imcivree, a drug for rare genetic obesity disorders caused by defects in the MC4R pathway.
Sells Imcivree, a daily injection, through specialty pharmacies to patients who first need a genetic diagnosis, so sales depend on finding eligible patients and winning insurers' coverage, and each stays on treatment for years. Orphan status, extra years of exclusivity for rare diseases, protects it. It is pursuing the wider group with hypothalamic obesity.
Moat: narrow (IP / patents, regulatory licence). Only approved therapy targeting specific genetic causes of severe obesity, protected by patents and orphan exclusivity.
Headquarters: Boston, Massachusetts, United States · Founded: 2008 · Employees: 414
Size Rhythm Pharmaceuticals (RYTM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.78B, the 906th largest of 3,117 United States companies the cockpit tracks. Shares closed at $112.28 on 6 Nov 2026.
Performance Over six months the shares gained 19.2%, against +6.7% for the median peer and -1.1% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 61.0% over the last twelve months (peer median +9.9%); the operating margin is -66.7% (peer median 16.9%).
Valuation It trades at 27.4× enterprise value to sales against a peer median of 4.5× (3rd most expensive of 19).
Capital Return on invested capital runs 163.0 points below its cost of capital (15.6% WACC).
Short interest Short interest is 16.0% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $281M | $190M | $130M | $77.4M | $23.6M |
| Revenue growth | — | +46% | +68% | +228% | — |
| Gross profit | $248M | $170M | $116M | $67.2M | $20.6M |
| EBITDA | -$186M | -$191M | -$264M | -$183M | -$178M |
| Net income | -$194M | -$197M | -$261M | -$185M | -$181M |
| Free cash flow | -$83.2M | -$117M | -$114M | -$136M | -$174M |
| Capital expenditure | $1.45M | $41.0M | $40.5M | $5.71M | $4.28M |
| Total debt | $106M | $243M | $257M | $107M | $77.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals RYTM | $7.78B | +19% | +61% | -67% | 27.4× | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 4.0× | 0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RYTM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.3% | +3.2% | 2nd highest of 21 |
| 6-month return | +19.2% | +6.7% | 10th highest of 21 |
| Distance from 52-week high | -8.1% | -13.8% | 7th highest of 21 |
| Revenue growth (TTM) | +61.0% | +9.9% | 2nd highest of 20 |
| Operating margin | -66.7% | 16.9% | 2nd lowest of 19 |
| EV / Sales | 27.4× | 4.5× | 3rd most expensive of 19 |
| ROIC minus cost of capital | -163.0 pp | +4.5 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | 27.4× | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 4.1× | 20.0% | +9.4% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% | +7.3% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 7.9× | 24.9% | +16.6% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | 2.4× | -9.1% | +6.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 2.0× | -6.1% | +9.3% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 6.4× | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 2.3× | 6.8% | +7.1% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 7.8× | 7.6% | +12.6% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 7.2× | 9.9% | +45.5% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 8.7× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 1.1× | -2.7% | +5.3% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 0.3× | -10.0% | +8.1% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 27.6× | 47.5% | +10.0% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 3.2× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 2.0× | -8.2% | +10.8% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $8.69B | -10% | +10% | 6% | 2.4× | 20.5% | +5.8% |
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 5.1× | -4.8% | +57.9% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |